AI synthesis of three filings for Veeva Systems Inc.
Veeva's fiscal year ends on January 31. The company calls the year ended January 31, 2026 "fiscal 2026" and the year ending January 31, 2027 "fiscal 2027". This page covers the annual report for fiscal 2026 and the second quarter of fiscal 2027, the three months ended July 31, 2026.
Business
From the fiscal 2026 annual report on Form 10-K (accession 0001393052-26-000014), updated where noted from the second-quarter fiscal 2027 Form 10-Q (accession 0001393052-26-000036).
Veeva sells industry-specific cloud software, data and consulting to the life sciences industry: pharmaceutical, biotechnology and medical device companies, contract research and contract sales organizations, and clinical research sites. Most of its revenue is recurring subscription fees. In fiscal 2026, subscriptions brought in $2,684.2 million of total revenue of $3,195.3 million (84%). Professional services and other (implementation, configuration, managed services, speakers-bureau logistics and Veeva Business Consulting) brought in the remaining $511.1 million (16%). Veeva reports one operating segment, but splits revenue into two product areas:
- R&D and Quality Solutions (Veeva Development Cloud and Veeva Quality Cloud) produced 55% of fiscal 2026 total revenue and 53% of subscription revenue. Development Cloud covers clinical trials (Veeva EDC, CDB, eTMF, CTMS, RTSM and site and patient applications), drug safety (Veeva Safety) and regulatory information management (Veeva RIM). Quality Cloud covers quality management (QMS, QualityDocs), lab and training applications. All of it runs on Veeva's own Vault platform. Some of these applications are also sold outside life sciences, mainly in North America and Europe. Veeva expects this area to keep growing as a share of revenue.
- Commercial Solutions (Veeva Commercial Cloud and Veeva Data Cloud) produced 45% of total revenue and 47% of subscription revenue. Commercial Cloud includes Vault CRM, the legacy Veeva CRM, Veeva Medical, PromoMats for commercial content and Crossix for marketing analytics and audience targeting. Data Cloud supplies reference, deep and transaction data: OpenData records on healthcare professionals, Veeva Link, Compass patient and prescriber data, and HCP Access.
Veeva AI adds agentic AI to the Vault platform and builds industry-specific AI agents into Veeva applications. The 10-Q says the company now describes its offerings as "applications, agents, data, and consulting". The agents use large language models from third parties, including Anthropic and Amazon, hosted on Amazon Bedrock. The 10-Q also names Aspen CRM, a newly announced CRM product for companies outside life sciences.
Customers. On January 31, 2026, Veeva had 1,552 customers, up from 1,477 a year earlier and 1,432 two years earlier. Of these, 767 bought Commercial Solutions and 1,196 bought R&D and Quality Solutions; some buy both. Customers range from the largest drug makers (the 10-K names Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Merck Sharp & Dohme and Novartis) to emerging biotechs. Revenue is concentrated: the top 10 customers accounted for 28% of total revenue in each of fiscal 2026, 2025 and 2024. Customers outside North America accounted for about 40% of fiscal 2026 revenue. CRM orders usually run for one year. Multi-year master subscription agreements generally let the customer terminate for convenience.
The CRM platform transition. Veeva's original CRM product, Veeva CRM, runs on the Salesforce platform. Veeva is moving those customers to Vault CRM, which runs on its own Vault platform, and will support Veeva CRM until December 31, 2029. Veeva's agreement with Salesforce expired on September 1, 2025. During a wind-down period that ends September 1, 2030, Veeva may not sell Salesforce-based applications to new customers. Each customer that existed at September 1, 2025 may not grow beyond 150% of the seats it had in use on that date. After September 1, 2030, Veeva may not sell Salesforce-based applications to anyone. Salesforce is also Veeva's main CRM competitor.
Competition. In CRM, Veeva competes mainly with Salesforce, which has built its own life sciences CRM application and licenses IQVIA's former CRM software. Data Cloud and Crossix compete with IQVIA, Ipsos, Definitive Health and smaller data providers. Development Cloud and Quality Cloud compete with IQVIA, Dassault Systèmes, OpenText, Oracle, Honeywell and smaller vendors, and also replace older client-server systems from Oracle and Microsoft. IQVIA, long both a rival and a litigant, settled all of its disputes with Veeva in August 2025.
Operations. Vault applications, including Vault CRM, are hosted on Amazon Web Services. Veeva CRM runs on Salesforce's infrastructure. Data centers are in the United States, the European Union, Japan, South Korea, Singapore, Australia and Brazil, with separate hosting for products used only in China. On January 31, 2026, Veeva had 7,928 employees, 637 more than a year earlier. It owns its headquarters in Pleasanton, California. Veeva is a Delaware public benefit corporation. Its stated public benefit purpose is to make the industries it serves more productive and to create high-quality jobs in its communities, and its directors must weigh that purpose and other stakeholders' interests alongside stockholder returns.
Capital allocation. Veeva has never paid a dividend and does not expect to. It returns cash to stockholders through a share repurchase program that its board authorized in January 2026.
Risk factors
From the fiscal 2026 Form 10-K (accession 0001393052-26-000014), as updated in the second-quarter fiscal 2027 Form 10-Q (accession 0001393052-26-000036).
The risks most specific to Veeva come from its CRM transition, its dependence on a single industry, and the arrival of AI.
- Losing CRM customers during the platform transition. Veeva says some customers have already chosen a competitor's CRM, and more may do so as it retires Veeva CRM. Salesforce has announced that certain large Veeva CRM customers have committed to buy its CRM, and a number of Veeva customers have said they intend to move to Salesforce. The migration to Vault CRM is complex and costly. It could cause outages if Vault has trouble handling the extra users, and failure would harm the business and the brand.
- Dependence on Salesforce until the wind-down ends. If the Salesforce platform became unavailable before Veeva expects, its business would suffer. Salesforce can end the wind-down period early in some cases, including a material breach by Veeva or certain intellectual property claims. If Veeva is acquired by certain named companies, Salesforce can terminate on at least 12 months' notice.
- Customer concentration and industry consolidation. With the top 10 customers at 28% of revenue, losing a large customer, or a large customer failing to renew or expand, would weigh on growth. Mergers between drug makers have led to cuts in user subscriptions and to non-renewals in the past. Veeva also expects closer scrutiny at renewal, and more pressure on price, as customers spend more with it.
- Exposure to the life sciences industry. Nearly all revenue comes from life sciences. The 10-Q names these pressures on customers:
- drug pricing measures, including the Inflation Reduction Act, administration proposals to tie U.S. drug prices to prices abroad, and direct price negotiations with manufacturers;
- possible limits on direct-to-consumer drug advertising, which would hit Crossix;
- cuts to funding and staffing at the FDA and NIH, and changes to Medicaid;
- harder funding conditions and bankruptcies among early-stage biotechs;
- fewer sales representatives as companies shift to digital channels, which has already reduced demand for Veeva CRM and other Commercial Solutions;
- tariffs on the industry's products and inputs.
- New products and AI. Growth depends on new products catching on, including Veeva AI and Aspen CRM. AI raises its own risks: accuracy, bias, privacy and controversy, plus fast-changing rules such as the EU AI Act. Veeva AI depends on third-party large language models, including Anthropic's. The 10-Q warns that providers or governments could suddenly suspend or restrict access to frontier models. Rivals that use AI better could take share.
- Security, privacy and regulation. Veeva handles sensitive data, including patient health data in Crossix and Compass. It operates under the EU and UK GDPR, China's PIPL, HIPAA and U.S. state privacy laws. A 2025 U.S. Department of Justice rule limits transfers of certain personal data to China and other designated countries. The EU Data Act, in force since September 12, 2025, lets EU customers cancel subscriptions without cause after giving notice and a transition period.
- Slower growth and pressure on margins. Total revenue grew 16%, 16% and 10% in fiscal 2026, 2025 and 2024, and subscription revenue grew 17%, 20% and 10%. Veeva warns that growth may slow. Costs that could squeeze profitability include large language model costs for Veeva AI, data purchases for Data Cloud, a larger sales force, and acquisitions.
- International operations and geopolitics. About 40% of revenue comes from outside North America. Veeva has an office, vendors and customers in Israel, and the 10-Q cites the conflict in the Middle East as a source of cyber and operating risk.
- Other risks. Professional services revenue and margins swing from quarter to quarter. Deferred revenue and billings are poor guides to future revenue because of billing timing and changes to renewal dates. A non-practicing entity has alleged that Veeva infringed its patents. The OECD's Pillar Two global minimum tax could raise tax costs. The company depends heavily on founder and CEO Peter P. Gassner. Its public benefit corporation status lets directors make decisions that do not maximize short-term stockholder value, including in a sale of the company.
Management's discussion: fiscal 2026 (year ended January 31, 2026)
From the fiscal 2026 Form 10-K (accession 0001393052-26-000014).
Fiscal 2026 combined mid-teens revenue growth with operating income that grew faster. Total revenue rose $449 million, or 16%, to $3,195.3 million. Subscription revenue rose 17% to $2,684.2 million. Of the $400 million subscription increase, $247 million came from R&D and Quality Solutions and $153 million from Commercial Solutions. Management attributed growth in both areas mainly to existing customers using more products, and to a lesser extent to the annual inflation price increase. Professional services and other revenue rose $49 million (11%) to $511.1 million, led by business consulting and implementation services. Subscription revenue by region was 60% North America, 28% Europe and 12% other, mainly Asia Pacific.
Gross margin rose to 76% from 75%. Subscription gross margin was 87% and professional services margin 18%. Cost of revenue rose $82 million: $42 million from services staff costs, plus $40 million in subscription costs, most of it ($36 million) for computing infrastructure and data. Operating expenses:
- Research and development rose 11% to $767.4 million, including $64 million more in employee compensation.
- Sales and marketing rose 8% to $428.8 million, including $29 million more in compensation.
- General and administrative rose 13% to $300.7 million, mainly because litigation settlement-related charges rose by a net $26 million. The fiscal 2026 charge, $30.6 million, matches the roughly $31 million in success fees Veeva paid to law firms after the IQVIA settlement. Management expected G&A to fall in fiscal 2027 as a result.
Operating income rose 33% to $916.4 million from $691.4 million. Other income, mostly interest, rose 22% to $278.1 million on higher cash and investment balances. The effective tax rate rose to 23.9% from 22.3%. The main reason was the indirect effect of the One Big Beautiful Bill Act: restoring immediate expensing of domestic R&D cut taxable income and with it the foreign-derived intangible income deduction. Net income was $908.9 million against $714.1 million, and diluted EPS was $5.44 against $4.32. Stock-based compensation was $472.7 million.
On the company's non-GAAP basis, which excludes stock-based compensation, amortization of purchased intangibles and litigation settlement-related charges, operating income was $1,433.8 million against $1,152.3 million.
Operating cash flow was $1,415 million against $1,090 million, helped by the tax law change. The first fiscal quarter is seasonally the strongest for cash because that is when Veeva collects its annual subscription billings. Investing activities used $1,104 million, mostly purchases of short-term investments. Financing used $9 million. Cash, cash equivalents and short-term investments totaled $6.6 billion at year end. In January 2026, the first month of the buyback, Veeva repurchased 801,735 shares for about $180 million at an average price of $224.43.
Current quarter: second quarter of fiscal 2027 (three months ended July 31, 2026)
From the second-quarter fiscal 2027 Form 10-Q (accession 0001393052-26-000036) and the results release furnished on Form 8-K (accession 0001393052-26-000032).
Revenue grew faster than in fiscal 2026, and operating income rose 40%. Part of that rise is because the prior-year quarter carried the IQVIA litigation charges. Total revenue was $928.0 million, up 18% from $789.1 million, and above the company's guidance of $902–905 million. Subscription revenue rose 16% to $766.8 million. Of the $108 million subscription increase, $68 million came from R&D and Quality Solutions and $40 million from Commercial Solutions. R&D and Quality subscription revenue was $419.4 million against $351.7 million; Commercial subscription revenue was $347.4 million against $307.5 million. Management attributed the growth to existing customers using more products and to the annual inflation price increase. Professional services and other revenue jumped 24% to $161.2 million on higher implementation and business consulting work. Subscription revenue by region was 60% North America, 29% Europe and 11% other.
Gross margin held at 75%: subscription at 86% and services at 22%. Operating expenses in the quarter:
- Research and development rose 16% to $222.9 million, including $24 million more in compensation.
- Sales and marketing rose 16% to $126.7 million, including $11 million more in compensation and $5 million more for marketing events.
- General and administrative fell 26% to $71.3 million because the year-earlier quarter included $31 million of litigation settlement-related charges.
Operating income rose 40% to $275.0 million from $195.9 million. Non-GAAP operating income rose 18% to $415.9 million from $352.6 million. Other income was $74.5 million. The effective tax rate fell to 21.8% from 24.5%, mainly because of a larger foreign-derived deduction-eligible income (FDDEI) deduction under the One Big Beautiful Bill Act, partly offset by tax shortfalls on equity compensation. Net income rose 37% to $273.4 million, and diluted EPS was $1.66 against $1.19.
For the first six months, revenue rose 17% to $1,810.9 million and net income was $534.4 million against $428.5 million. Operating cash flow for the six months was $1,366 million against $1,116 million. The company credited higher collections and lower income tax payments under the new tax law. It expects that law to keep reducing cash taxes for the rest of the year but cannot yet estimate by how much. Investing activities used $452 million, including the Ostro acquisition described below. Financing activities used $522 million, against $136 million provided a year earlier, mainly because of share repurchases and smaller proceeds from option exercises. Cash, cash equivalents and short-term investments reached $7.2 billion on July 31, 2026, and the balance sheet shows no borrowings. Deferred revenue was $1,310.5 million, against $1,488.8 million at January 31, 2026, reflecting the seasonal billing pattern described above. Shares outstanding were 161,834,760.
Change to employee equity. In April 2026, Veeva stopped making annual stock option grants to employees other than the CEO. Instead it grants restricted stock units that generally vest in full after four years of service. These grants are not expected to recur each year, and employees will generally hold only one at a time.
Acquisitions. Veeva has made two acquisitions this fiscal year. In March 2026 it bought Ostro (Rise Healthcare Tech, Inc.), whose AI chat platform gives patients and doctors immediate, compliant answers. According to the first-quarter results release, Ostro was already delivering conversational AI for more than 50 brands. Veeva also acquired Copli during the second quarter. The second-quarter results release mentions the deal in its AI highlights but does not describe Copli's business, and the 10-Q's acquisitions note does not mention it.
Product momentum. The second-quarter results release reported progress across the product lines. Veeva launched Veeva Falcon MLR to automate content reviews. Veeva Safety passed 100 customers, and Quality Cloud added more than 30 new customers. In clinical trials, a large enterprise biopharma added Veeva EDC to the eTMF, CTMS and Study Startup applications it already used.
Outlook. Management said second-quarter results beat guidance on every metric, and it raised its full-year fiscal 2027 outlook at both the first-quarter and second-quarter results. The operating income and EPS guidance is on the company's non-GAAP basis; the revenue guidance is total revenues. Veeva does not give GAAP targets for operating income or EPS because it cannot reasonably predict excluded items such as stock-based compensation.
Subsequent events
From the second-quarter fiscal 2027 Form 10-Q (accession 0001393052-26-000036), the second-quarter results release (accession 0001393052-26-000032) and the fiscal 2026 Form 10-K (accession 0001393052-26-000014).
The 10-Q for the quarter ended July 31, 2026 has no subsequent-events note. It discloses no acquisition, divestiture, borrowing or litigation outcome after the quarter end, and it says Veeva is not party to any legal proceeding expected to have a material adverse effect.
The main business development after the quarter was in CRM. Two top-20 biopharmas and one large enterprise biopharma committed to Vault CRM in August 2026, according to the results release. That moves Veeva closer to the goal it set at the end of fiscal 2026: it then had 10 top-20 commitments and expected about 14 of the top 20 to commit.
The fiscal 2026 10-K's subsequent-events note covered the Ostro acquisition. It said the deal closed on March 10, 2026 for about $100 million in cash and long-term equity retention grants, and that the accounting was still being assessed. The 10-Q later gave the closing date as March 9, 2026. It put the purchase consideration at $90 million ($70 million net of cash acquired), excluding equity awards to Ostro employees that are accounted for separately. The 10-Q figures are the later and more detailed ones.
AI synthesis of events in 16 filings
Filings that contain financial statements
Veeva furnishes its quarterly results as an Exhibit 99.1 press release to a Form 8-K (Item 2.02). Each release includes condensed consolidated financial statements.
- Form 8-K filed August 26, 2026, accession 0001393052-26-000032: second quarter of fiscal 2027 (three and six months ended July 31, 2026). Holds the condensed consolidated balance sheet (July 31, 2026 and January 31, 2026), statements of comprehensive income (three and six months), cash flow statement (six months), and a GAAP to non-GAAP reconciliation.
- Form 8-K filed June 3, 2026, accession 0001393052-26-000022: first quarter of fiscal 2027 (quarter ended April 30, 2026). Holds the balance sheet and income statement.
- Form 8-K filed March 4, 2026, accession 0001393052-26-000007: fourth quarter and full fiscal year 2026 (year ended January 31, 2026). Holds the consolidated balance sheet and income statement.
- Form 8-K filed November 20, 2025, accession 0001393052-25-000074: third quarter of fiscal 2026 (quarter ended October 31, 2025).
- Form 8-K filed August 27, 2025, accession 0001393052-25-000063: second quarter of fiscal 2026 (quarter ended July 31, 2025).
- Form 8-K filed May 28, 2025, accession 0001393052-25-000037: first quarter of fiscal 2026 (quarter ended April 30, 2025).
Earnings and guidance
August 26, 2026 - Q2 fiscal 2027 results (accession 0001393052-26-000032). Total revenues were $928.0 million, up 18% from $789.1 million a year earlier; subscription revenues were $766.8 million, up 16%. Operating income was $275.0 million (up 40%) and non-GAAP operating income $415.9 million (up 18%). Net income was $273.4 million and diluted EPS $1.66 (non-GAAP $2.35). Management said results exceeded guidance on all metrics and that its full-year view improved across the board.
- Guidance raised for fiscal 2027 (year ending January 31, 2027): total revenues of $3,682 to $3,687 million (previously $3,635 to $3,645 million), non-GAAP operating income of about $1,640 million (previously about $1,610 million), and non-GAAP diluted EPS of approximately $9.21 (previously approximately $9.05).
- Third quarter guidance (quarter ending October 31, 2026): revenues of $932 to $935 million, non-GAAP operating income of $417 to $420 million, and non-GAAP diluted EPS of $2.33 to $2.34.
- Highlights cited: more than 180 Vault CRM customers live, with total top 20 biopharma commitments to Vault CRM reaching 12 globally; Veeva Falcon (agentic labor platform for clinical, regulatory and safety) has five early adopters and is on track for initial go-lives this year.
June 3, 2026 - Q1 fiscal 2027 results (accession 0001393052-26-000022). Revenues were $882.9 million, up 16%; subscription revenues $730.2 million, up 15%. Non-GAAP operating income was $395.4 million and diluted EPS $1.57 (non-GAAP $2.24). Results exceeded guidance on all metrics and full-year guidance was raised from the March figures (revenues $3,585 to $3,600 million, non-GAAP operating income about $1,590 million, non-GAAP EPS about $8.85) to revenues of $3,635 to $3,645 million, non-GAAP operating income of about $1,610 million and non-GAAP EPS of approximately $9.05.
March 4, 2026 - Q4 and fiscal 2026 results (accession 0001393052-26-000007). Fiscal 2026 total revenues were $3,195.3 million, up 16%; subscription revenues $2,684.2 million, up 17%. Operating income was $916.4 million (up 33%), net income $908.9 million and diluted EPS $5.44 (non-GAAP $8.10). Fourth quarter revenues were $836.0 million. Initial fiscal 2027 guidance: revenues of $3,585 to $3,600 million, non-GAAP operating income of about $1,590 million, non-GAAP EPS of approximately $8.85. The release restated the company's target of a $6 billion revenue run rate by 2030.
Earlier results: Q3 fiscal 2026 on November 20, 2025 (accession 0001393052-25-000074), Q2 fiscal 2026 on August 27, 2025 (0001393052-25-000063) and Q1 fiscal 2026 on May 28, 2025 (0001393052-25-000037).
Capital actions
January 5, 2026 - share repurchase program (accession 0001393052-26-000003). The board authorized repurchases of up to $2 billion of Class A common stock, with a two-year term, via open market purchases, privately negotiated transactions or Rule 10b5-1 plans. It was the company's first repurchase program. The program does not obligate Veeva to buy any set number of shares and can be suspended at any time.
Execution is reported in the Form 10-Q for the quarter ended July 31, 2026 (accession 0001393052-26-000036): the company repurchased 1,408,414 shares in the second quarter at an average of $174.48 (about $245.7 million) and 2,663,443 shares in the six months at an average of $175.28 (about $466.8 million), all in open market transactions. About $1.4 billion remained available at July 31, 2026.
Acquisitions (both closed)
- Ostro (Rise Healthcare Tech, Inc.) - closed March 9, 2026. The Form 10-Q for the quarter ended July 31, 2026 (accession 0001393052-26-000036) states Veeva "acquired all outstanding stock" of Rise Healthcare Tech, Inc. for total consideration of $90 million ($70 million net of cash acquired); goodwill of $44.4 million and purchased intangibles of $25.5 million were recorded. No separate Form 8-K was filed for the deal. The June 3, 2026 release (0001393052-26-000022) describes Ostro, an AI-driven conversational platform, as "acquired in March".
- Copli - closed in the second quarter of fiscal 2027 (May through July 2026). The August 26, 2026 release (0001393052-26-000032) says the company "acquired Copli in the quarter." No price or terms are disclosed in the filings reviewed.
Litigation and legal
August 13, 2025 (reported August 18, 2025) - IQVIA settlement (accession 0001393052-25-000058). Veeva and IQVIA settled all litigation pending since 2017. Neither side pays damages and all claims and counterclaims are dismissed with prejudice. The parties also entered long-term commercial and clinical partnership and data-access agreements. Veeva stated it would make a one-time payment of approximately $31 million to law firms under previously disclosed outcome-based fee arrangements.
Management and board changes
- August 20, 2026 (accession 0001213900-26-092096): Dan Rizzo appointed EVP, Sales, Consulting, and Services, effective October 2, 2026. He succeeds Thomas D. Schwenger, President and Chief Customer Officer, who resigned on August 18, 2026 effective October 2, 2026 to become CEO of a long-standing Veeva partner.
- April 20, 2026 (accession 0001393052-26-000018): Josh Faddis, Senior Vice President and General Counsel, intends to retire effective November 1, 2026 and move to a part-time advisor role; a successor will be appointed at that time.
- December 10, 2025 (accession 0001393052-25-000082): Vipin Kondath, Corporate Controller since April 2022, appointed principal accounting officer effective December 12, 2025, following Chief Accounting Officer Kristine Diamond's resignation effective December 11, 2025 (announced November 18, 2025, accession 0001393052-25-000070).
- March 2025 (accession 0001393052-25-000010): Director Tina Hunt informed the board of her intention to retire, effective immediately before the 2025 annual meeting.
Annual meetings
- June 17, 2026 (accession 0001393052-26-000029): All nine director nominees were elected. Matthew J. Wallach received the lowest support (about 84.2 million for, 47.9 million against), followed by Gordon Ritter (about 97.1 million for, 34.9 million against); Mark Carges received 105.5 million for and 26.5 million against.
- June 18, 2025 (accession 0001393052-25-000052): Directors elected at the 2025 annual meeting.
No debt issuance, dividend, stock split, impairment, restructuring or going-concern item appears in the 8-K filings from March 2025 through August 2026.
Financials
Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. A figure with no link was either derived by AI, such as a margin, free cash flow or a trailing-twelve-month total, or taken from a filing that does not tag its numbers, such as an earnings release.
About this file
| Ticker | VEEV |
|---|---|
| CIK | 0001393052 |
| Company | Veeva Systems Inc. |
| Business type | software (subscription / SaaS) |
| Schema template | standard (technology): revenue split subscription vs. professional services, gross profit, operating expenses, operating income, net income, EPS; cash and investments, deferred revenue, assets, liabilities, equity; operating cash flow, capital spending, free cash flow, buybacks |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual US dollars (not thousands); per-share figures in dollars; share counts in actual shares |
VEEV annual income statement, balance sheet and cash flow
Taken from the SEC filings and normalized to actual dollars.
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Period start | 2025-02-01 | 2024-02-01 | 2023-02-01 |
| Period end | 2026-01-31 | 2025-01-31 | 2024-01-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 10-K | 10-K | 10-K |
| Balance sheet | |||
| Cash and cash equivalents | 1,421,233,000 | 1,118,785,000 | |
| Short term investments | 5,139,581,000 | 4,031,442,000 | |
| Accounts receivable net | 1,259,737,000 | 1,016,356,000 | |
| Unbilled accounts receivable | 50,609,000 | 40,761,000 | |
| Total current assets | 7,997,630,000 | 6,308,802,000 | |
| Goodwill | 439,877,000 | 439,877,000 | |
| Intangible assets net | 30,314,000 | 44,460,000 | |
| Total assets | 8,979,343,000 | 7,339,756,000 | |
| Deferred revenue current | 1,488,819,000 | 1,273,978,000 | |
| Total current liabilities | 1,637,056,000 | 1,398,404,000 | |
| Total liabilities | 1,764,591,000 | 1,507,383,000 | |
| Retained earnings | 4,363,501,000 | 3,454,595,000 | |
| Total stockholders equity | 7,214,752,000 | 5,832,373,000 | |
| Shares outstanding | 163,778,271 | 162,583,789 | |
| Cash flow | |||
| Depreciation and amortization | 37,972,000 | 39,383,000 | 32,628,000 |
| Operating cash flow | 1,415,225,000 | 1,090,051,000 | 911,339,000 |
| Purchases of short term investments | -3,133,080,000 | -2,581,968,000 | -2,697,968,000 |
| Maturities and sales of short term investments | 2,057,849,000 | 1,902,349,000 | 1,647,813,000 |
| Capex | -29,131,000 | -20,519,000 | -26,196,000 |
| Investing cash flow | -1,104,362,000 | -700,138,000 | -1,076,351,000 |
| Proceeds from stock option exercises | 253,863,000 | 105,538,000 | 62,687,000 |
| Repurchases of common stock | -169,949,000 | 0 | 0 |
| Taxes paid for net share settlement | -93,247,000 | -79,423,000 | -78,875,000 |
| Financing cash flow | -9,333,000 | 26,115,000 | -16,188,000 |
| Net change in cash and restricted cash | 302,449,000 | 414,293,000 | -182,980,000 |
| Cash paid for income taxes | 229,965,000 | 322,048,000 | 134,473,000 |
| Free cash flow | 1,386,094,000 | 1,069,532,000 | 885,143,000 |
| Income statement | |||
| Subscription revenue | 2,684,194,000 | 2,284,659,000 | 1,901,593,000 |
| Professional services and other revenue | 511,117,000 | 461,960,000 | 462,080,000 |
| Total revenues | 3,195,311,000 | 2,746,619,000 | 2,363,673,000 |
| Cost of subscription | 362,888,000 | 323,070,000 | 290,577,000 |
| Cost of professional services and other | 419,131,000 | 376,566,000 | 386,714,000 |
| Total cost of revenues | 782,019,000 | 699,636,000 | 677,291,000 |
| Gross profit | 2,413,292,000 | 2,046,983,000 | 1,686,382,000 |
| Research and development | 767,386,000 | 693,078,000 | 629,031,000 |
| Sales and marketing | 428,798,000 | 396,726,000 | 381,472,000 |
| General and administrative | 300,739,000 | 265,744,000 | 246,545,000 |
| Total operating expenses | 1,496,923,000 | 1,355,548,000 | 1,257,048,000 |
| Operating income | 916,369,000 | 691,435,000 | 429,334,000 |
| Other income net | 278,139,000 | 227,946,000 | 158,689,000 |
| Income before income taxes | 1,194,508,000 | 919,381,000 | 588,023,000 |
| Income tax provision | 285,602,000 | 205,243,000 | 62,318,000 |
| Net income | 908,906,000 | 714,138,000 | 525,705,000 |
| Basic EPS | 5.55 | 4.41 | 3.27 |
| Diluted EPS | 5.44 | 4.32 | 3.22 |
| Basic shares | 163,667,000 | 161,879,000 | 160,532,000 |
| Diluted shares | 166,995,000 | 165,232,000 | 163,486,000 |
| Stock based compensation | 472,703,000 | 437,350,000 | 393,733,000 |
VEEV quarterly income statement, balance sheet and cash flow
Taken from the SEC filings and normalized to actual dollars.
| Q2 FY2027 | Q2 FY2026 | |
|---|---|---|
| Fiscal quarter | 2 | 2 |
| Period start | 2026-05-01 | 2025-05-01 |
| Period end | 2026-07-31 | 2025-07-31 |
| Period type | three months | three months |
| Source accession | 10-Q | 10-Q |
| Cash flow source accession | 0001393052-26-000032 | 0001393052-26-000032 |
| Balance sheet | ||
| Cash and cash equivalents | 1,812,012,000 | |
| Short term investments | 5,430,935,000 | |
| Accounts receivable net | 496,677,000 | |
| Unbilled accounts receivable | 68,970,000 | |
| Total current assets | 7,946,227,000 | |
| Goodwill | 492,991,000 | |
| Intangible assets net | 55,647,000 | |
| Total assets | 9,060,223,000 | |
| Deferred revenue current | 1,310,498,000 | |
| Total current liabilities | 1,455,950,000 | |
| Total liabilities | 1,628,774,000 | |
| Retained earnings | 4,897,866,000 | |
| Total stockholders equity | 7,431,449,000 | |
| Shares outstanding | 161,834,760 | |
| Cash flow | ||
| Operating cash flow | 238,709,000 | 238,433,000 |
| Investing cash flow | -63,540,000 | -389,272,000 |
| Financing cash flow | -259,308,000 | 115,689,000 |
| Income statement | ||
| Subscription revenue | 766,764,000 | 659,183,000 |
| Professional services and other revenue | 161,199,000 | 129,898,000 |
| Total revenues | 927,963,000 | 789,081,000 |
| Cost of subscription | 105,677,000 | 93,830,000 |
| Cost of professional services and other | 126,335,000 | 101,423,000 |
| Total cost of revenues | 232,012,000 | 195,253,000 |
| Gross profit | 695,951,000 | 593,828,000 |
| Research and development | 222,918,000 | 192,677,000 |
| Sales and marketing | 126,701,000 | 109,439,000 |
| General and administrative | 71,314,000 | 95,804,000 |
| Total operating expenses | 420,933,000 | 397,920,000 |
| Operating income | 275,018,000 | 195,908,000 |
| Other income net | 74,512,000 | 69,456,000 |
| Income before income taxes | 349,530,000 | 265,364,000 |
| Income tax provision | 76,101,000 | 65,055,000 |
| Net income | 273,429,000 | 200,309,000 |
| Basic EPS | 1.68 | 1.23 |
| Diluted EPS | 1.66 | 1.19 |
| Basic shares | 162,344,000 | 163,496,000 |
| Diluted shares | 165,057,000 | 167,685,000 |
| Stock based compensation | 136,803,000 | 121,966,000 |
VEEV year-to-date income statement and cash flow
Taken from the SEC filings and normalized to actual dollars.
| H1 FY2027 | H1 FY2026 | |
|---|---|---|
| Period start | 2026-02-01 | 2025-02-01 |
| Period end | 2026-07-31 | 2025-07-31 |
| Period type | six months | six months |
| Source accession | 10-Q | 10-Q |
| Cash flow | ||
| Depreciation and amortization | 22,458,000 | 19,948,000 |
| Operating cash flow | 1,365,825,000 | 1,115,591,000 |
| Purchases of short term investments | -1,706,632,000 | -1,452,857,000 |
| Maturities and sales of short term investments | 1,345,987,000 | 1,023,691,000 |
| Capex | -9,773,000 | -12,213,000 |
| Acquisitions net of cash acquired | -81,833,000 | 0 |
| Investing cash flow | -452,251,000 | -441,379,000 |
| Proceeds from stock option exercises | 17,143,000 | 182,297,000 |
| Repurchases of common stock | -472,673,000 | 0 |
| Taxes paid for net share settlement | -66,304,000 | -46,228,000 |
| Financing cash flow | -521,834,000 | 136,069,000 |
| Net change in cash and restricted cash | 390,909,000 | 811,646,000 |
| Cash paid for income taxes | 151,543,000 | 126,683,000 |
| Free cash flow | 1,356,052,000 | 1,103,378,000 |
| Income statement | ||
| Subscription revenue | 1,496,939,000 | 1,293,951,000 |
| Professional services and other revenue | 313,972,000 | 254,173,000 |
| Total revenues | 1,810,911,000 | 1,548,124,000 |
| Cost of subscription | 204,780,000 | 172,176,000 |
| Cost of professional services and other | 248,156,000 | 196,901,000 |
| Total cost of revenues | 452,936,000 | 369,077,000 |
| Gross profit | 1,357,975,000 | 1,179,047,000 |
| Research and development | 431,241,000 | 376,710,000 |
| Sales and marketing | 237,818,000 | 208,067,000 |
| General and administrative | 140,786,000 | 164,630,000 |
| Total operating expenses | 809,845,000 | 749,407,000 |
| Operating income | 548,130,000 | 429,640,000 |
| Other income net | 148,930,000 | 134,545,000 |
| Income before income taxes | 697,060,000 | 564,185,000 |
| Income tax provision | 162,695,000 | 135,686,000 |
| Net income | 534,365,000 | 428,499,000 |
| Basic EPS | 3.28 | 2.63 |
| Diluted EPS | 3.22 | 2.56 |
| Basic shares | 162,836,000 | 163,129,000 |
| Diluted shares | 166,072,000 | 167,272,000 |
| Stock based compensation | 256,062,000 | 234,176,000 |
VEEV trailing twelve month income statement and cash flow
Derived by AI from the figures the filings report. No filing prints these, so none of them is linked.
| TTM ended July 31, 2026 | |
|---|---|
| Period start | 2025-08-01 |
| Period end | 2026-07-31 |
| Period type | trailing twelve months |
| Source accession | 10-Q |
| Source accessions | 10-K, 10-Q |
| Derived | yes |
| Cash flow | |
| Operating cash flow | 1,665,459,000 |
| Capex | -26,691,000 |
| Depreciation and amortization | 40,482,000 |
| Repurchases of common stock | -642,622,000 |
| Free cash flow | 1,638,768,000 |
| Income statement | |
| Subscription revenue | 2,887,182,000 |
| Professional services and other revenue | 570,916,000 |
| Total revenues | 3,458,098,000 |
| Cost of subscription | 395,492,000 |
| Cost of professional services and other | 470,386,000 |
| Total cost of revenues | 865,878,000 |
| Gross profit | 2,592,220,000 |
| Research and development | 821,917,000 |
| Sales and marketing | 458,549,000 |
| General and administrative | 276,895,000 |
| Total operating expenses | 1,557,361,000 |
| Operating income | 1,034,859,000 |
| Other income net | 292,524,000 |
| Income before income taxes | 1,327,383,000 |
| Income tax provision | 312,611,000 |
| Net income | 1,014,772,000 |
| Stock based compensation | 494,589,000 |
Adjustments
| Splits applied | none |
|---|---|
| ADR ratio | n/a |
| FX | none - Veeva reports in US dollars |
Notes
- Veeva Systems' fiscal year ends January 31. FY2026 is the year ended January 31, 2026; Q2 FY2027 is the quarter ended July 31, 2026.
- Sources: the annual figures for FY2026, FY2025 and FY2024 and the January 31, 2026 and 2025 balance sheets come from the FY2026 Form 10-K (accession 0001393052-26-000014). The Q2 FY2027 and Q2 FY2026 income statements, the July 31, 2026 balance sheet, and the six-month figures come from the Q2 FY2027 Form 10-Q (accession 0001393052-26-000036).
- The 10-Q presents cash flows only for the six months ended July 31. The three-month operating, investing and financing cash flows shown for Q2 FY2027 and Q2 FY2026 come from the GAAP-basis lines of the reconciliation table in the Q2 FY2027 earnings release furnished as Exhibit 99.1 to the Form 8-K filed August 26, 2026 (accession 0001393052-26-000032), recorded on each quarter as cash_flow_source_accession. The release does not print three-month capital spending, so no quarterly free cash flow is given.
- The FY2024 annual period carries an income statement and cash flows but no balance sheet, because the FY2026 10-K presents balance sheets only as of January 31, 2026 and 2025.
- The July 31, 2026 balance sheet is carried on the Q2 FY2027 quarter; the January 31, 2026 balance sheet, which the 10-Q also prints as its comparative, is carried on FY2026 and taken from the 10-K. The two agree.
- capex is the investing line Veeva's cash flow statement captions 'Long-term assets'; the filings describe investing activities as purchases of marketable securities, net of maturities, plus capital expenditures, and this is the only capital-spending line. free_cash_flow is operating cash flow less that line. Veeva does not present a free cash flow figure in these filings; it is calculated here.
- stock_based_compensation in each income statement is the total stock-based compensation disclosed in the footnote beneath the statement of comprehensive income; it is already included in the cost and expense lines above it.
- Share counts: basic_shares and diluted_shares are weighted averages printed in thousands and stated here in actual shares. shares_outstanding is the period-end count: 163,778,271 and 162,583,789 at January 31, 2026 and 2025 from the 10-K balance sheet, and 161,834,760 at July 31, 2026 from the 10-Q statement of stockholders' equity.
- Veeva's balance sheets carry no borrowings line; its liabilities are mainly deferred revenue, accrued items and lease liabilities. No total debt figure is recorded because the filings print none.
- The trailing-twelve-months block (August 1, 2025 to July 31, 2026) is calculated as FY2026 plus the six months ended July 31, 2026 less the six months ended July 31, 2025. Per-share earnings and share counts are not summed across periods, so the block carries no EPS.
- The repurchase lines for FY2025, FY2024 and the six months ended July 31, 2025 are zero because the cash flow statements print a dash for them. Of the periods these filings present, FY2026 is the first with share repurchases.
- Cash flow from acquisitions in the six months ended July 31, 2026 ($81.8 million, net of cash acquired) includes the acquisition the Q2 FY2027 10-Q (accession 0001393052-26-000036) describes as Rise Healthcare Tech, Inc. ('Ostro'), which that 10-Q puts at $90 million of total consideration, or $70 million net of cash acquired; the 10-Q does not itemize the rest of the line. The Q2 FY2027 earnings release (accession 0001393052-26-000032) says Veeva also acquired Copli in the quarter but does not state a price for it.
- No stock splits, currency translation or ADR adjustments apply. Veeva reports in US dollars and its common stock trades directly on the NYSE. All figures are in actual US dollars, scaled up from the thousands the statements print.
Uncertainties
- Three-month cash flows for Q2 FY2027 and Q2 FY2026 come from the earnings release, not the 10-Q, which prints only six-month cash flows. The six-month GAAP operating, investing and financing totals in the release match the 10-Q exactly.
- The trailing-twelve-month figures are calculated, not printed in any filing.
Company details
| Name | Veeva Systems Inc |
|---|---|
| Ticker | VEEV |
| CIK | 0001393052 |
| Exchange | NYSE |
| State | California |
| Incorporation | Delaware |
| SIC | 7372 |
| Office | Technology |
| Industry | Services-Prepackaged Software |
Fiscal period
| Fiscal year | 2027 |
|---|---|
| Fiscal period | Q2 |
| Tag | FY27Q2 |
| Period end | 2026-07-31 |
| Form | 10-Q |
| Accession | 0001393052-26-000036 |
| Fiscal year end | 0131 |
| Source | facts |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Source |
|---|---|---|---|---|---|---|---|---|---|
| annual | no | 10-K | 2026 | FY | FY26 | 2026-01-31 | 2026-03-20 | 0001393052-26-000014 | reported |
| quarterly | yes | 10-Q | 2027 | Q2 | FY27Q2 | 2026-07-31 | 2026-08-27 | 0001393052-26-000036 | facts |